Summary
BO1 Chart
BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Jefferies London Healthcare Conference 2025 Transcript
BioCryst Pharmaceuticals, Inc. ( BCRX ) Jefferies London Healthcare Conference 2025 November 19, 2025 12:00 PM EST Company Participants Jon Stonehouse - CEO & Executive Director Charles Gayer - President & Chief Commercial Officer Babar Ghias - CFO & Head of Corporate Development Conference Call Participants Maurice Raycroft - Jefferies LLC, Research Division Presentation Maurice Raycroft Jefferies LLC, Research Division Hi, everyone. My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies.
BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2025 Earnings Call Transcript
BioCryst Pharmaceuticals, Inc. ( BCRX ) Q3 2025 Earnings Call November 3, 2025 8:30 AM EST Company Participants Nick Wilder Jon Stonehouse - CEO & Executive Director Charles Gayer - President & Chief Commercial Officer William Sheridan - Chief Development Officer Babar Ghias - CFO & Head of Corporate Development Conference Call Participants Laura Chico - Wedbush Securities Inc., Research Division Stacy Ku - TD Cowen, Research Division Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Maurice Raycroft - Jefferies LLC, Research Division Brian Abrahams - RBC Capital Markets, Research Division Jonathan Wolleben - Citizens JMP Securities, LLC, Research Division John Todaro - Needham & Company, LLC, Research Division Huidong Wang - Barclays Bank PLC, Research Division Presentation Operator Good day, and welcome to BioCryst Third Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded.
BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: Should You Buy?
BioCryst (BCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioCryst Pharmaceuticals Inc. (BO1) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has BioCryst Pharmaceuticals Inc. ever had a stock split?
BioCryst Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Jon P. Stonehouse CEO | XFRA Exchange | US09058V1035 ISIN |
| US Country | 580 Employees | - Last Dividend | - Last Split | 3 Mar 1994 IPO Date |
Overview
BioCryst Pharmaceuticals, Inc. is a pioneering biotechnology company focused on the development of oral small-molecule and protein therapeutics aimed at treating rare diseases. Established in 1986, the company is positioned at the forefront of medical research, utilizing cutting-edge technology and innovative approaches to create treatments that significantly improve patient outcomes. Headquartered in Durham, North Carolina, BioCryst maintains a global presence through strategic collaborations and in-license relationships with various internationally recognized institutions and companies. These partnerships enhance the firm's research capabilities and facilitate the broad distribution of its products, reinforcing its commitment to addressing unmet medical needs worldwide.
Products and Services
- Peramivir Injection (RAPIVAB, RAPIACTA, PERAMIFLU)
This product is an intravenous neuraminidase inhibitor designed for the treatment of acute uncomplicated influenza. By targeting the neuraminidase enzyme, peramivir prevents the release of new virus particles, effectively limiting the spread of the influenza virus within the body. Its intravenous administration ensures rapid delivery and action, offering a significant benefit for patients requiring immediate treatment.
- ORLADEYO (Oral Serine Protease Inhibitor)
ORLADEYO is an innovative treatment for hereditary angioedema, a rare and potentially life-threatening genetic condition. As an oral serine protease inhibitor, ORLADEYO works by inhibiting the activity of specific enzymes involved in the cascade of events that lead to angioedema attacks. This treatment represents a significant advancement in the management of hereditary angioedema, providing patients with a convenient oral medication option.
- BCX10013 (Oral Factor D Inhibitor)
Currently under development, BCX10013 is an oral factor D inhibitor targeting complement-mediated diseases. Factor D is a crucial enzyme in the complement pathway, a part of the immune system that plays a key role in inflammation and cell destruction. By inhibiting factor D, BCX10013 aims to provide a novel treatment option for patients with complement-mediated conditions, showcasing BioCryst's commitment to expanding its portfolio of innovative therapies.
Contact Information
